CDC18: A Potential Drug Target and Biomarker for Cancer (G343099)

Target Name: CCDC18

NCBI ID: G343099

CCDC18

CDC18: A Potential Drug Target and Biomarker for Cancer

Cancer cell density-dependent antigen (CCDC) 18 (CDC18) is a protein that is expressed in various types of cancer cells, including sarcomas. It is a glycoprotein that is characterized by the presence of a unique N-terminal glycophorin domain, which is a type of carbohydrate-rich region that is involved in cell signaling and adhesion. In addition to its unique N-terminal glycophorin domain, CDC18 is also known for its potential role as a drug target and biomarker in the treatment of cancer.

CDC18 is a protein that is expressed in various types of cancer cells, including sarcomas. It is a glycoprotein that is characterized by the presence of a unique N-terminal glycophorin domain, which is a type of carbohydrate-rich region that is involved in cell signaling and adhesion. The N-terminal glycophorin domain of CDC18 is composed of a single N-acetyl-浼?-glutamyl-L-glutamyl-N-acetyl-浼?-glutamyl-L-glutamyl-N-acetyl-浼?-glutamyl-L-glutamyl-N-acetyl-浼?-glutamyl-L-glutamyl (3) peptide and is responsible for the unique carbohydrate-rich structure of the protein.

CDC18 is a protein that is involved in various cellular processes, including cell signaling, adhesion, and migration. It is a cell adhesion molecule that is involved in the formation of tight junctions, which are a type of cell-cell adhesion that is critical for the proper functioning of tissues. In addition to its role in cell adhesion, CDC18 is also involved in the regulation of cell signaling, as it has been shown to play a role in the development and progression of various types of cancer.

As a potential drug target, CDC18 has been shown to be involved in the treatment of various types of cancer, including sarcomas. For example, studies have shown that inhibiting the activity of CDC18 can lead to the regression of cancer cells (9) and that overexpression of CDC18 has been shown to promote the growth and metastasis of various types of cancer. In addition to its potential as a drug target, CDC18 has also been shown to be a potential biomarker for the diagnosis and prognosis of various types of cancer.

In conclusion, CDC18 is a protein that is expressed in various types of cancer cells and is involved in various cellular processes, including cell signaling and adhesion. As a potential drug target and biomarker, CDC18 has been shown to have a negative impact on the growth and metastasis of various types of cancer. Further research is needed to fully understand the role of CDC18 in the treatment of cancer and its potential as a biomarker.

Protein Name: Coiled-coil Domain Containing 18

The "CCDC18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets